ARCHIVES

FDA Discloses Responses, Toxicities For Burzynski’s “Antineoplastons”

This article is from The Cancer Letter archive.

Vol. 24 No. 16 | April 24, 1998

Download PDF Visit The Full Archive

Related Articles

Research Program For Biological Response Modifiers Outlined By DCT board Subcommittee

November 16, 1979

Tacoma Hospital Finds Cancer DRGs Are Profitable

February 17, 1984

NIH “Just In Time” Procedure Expanded For Two Awards

April 12, 1996

ACCC Members Hear How Community Cancer Programs Are Developed

February 11, 1977

Conference On Delayed Consequences Of Cancer Therapy Scheduled Jan. 9-11

January 3, 1975

NCI Advisors To Evaluate SPORE Program; Large Grants to Be Weighed Against R01s

December 12, 1997